We Think Asymchem Laboratories (Tianjin) (SZSE:002821) Can Stay On Top Of Its Debt
We Think Asymchem Laboratories (Tianjin) (SZSE:002821) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We can see that Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) does use debt in its business. But the more important question is: how much risk is that debt creating?
贺华德·马克斯(Howard Marks)很好地表达了他的观点,他说,与其担心股价的波动性,“我担心的是永久性损失的可能性...我所认识的每位实际投资者都在担心这个。”所以,当您考虑任何一只股票的风险时,需要考虑债务,因为过多的债务可能会拖垮一家公司。我们可以看到,凯莱英(临时代码)(建议股票代码:002821)的业务中确实使用了债务。但更重要的问题是:这些债务带来了多大的风险?
What Risk Does Debt Bring?
债务带来了什么风险?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.
当公司无法通过自由现金流或以有吸引力的价格筹集资本来轻松地履行债务时,债务和其他负债将对公司构成风险。资本主义的本质是‘创造性破坏’,失败的企业无情地被银行家清算。然而,更常见(但仍然昂贵)的情况是公司必须通过低廉的股票价格稀释股东权益才能将债务控制在可控范围内。话虽如此,最常见的情况是公司合理地管理其债务并在其自身利益之内。在考虑企业使用了多少债务时,需要首先查看其现金和债务的情况。
What Is Asymchem Laboratories (Tianjin)'s Net Debt?
凯莱英(临时代码)的净债务是多少?
The image below, which you can click on for greater detail, shows that at March 2024 Asymchem Laboratories (Tianjin) had debt of CN¥12.2m, up from none in one year. However, its balance sheet shows it holds CN¥8.98b in cash, so it actually has CN¥8.97b net cash.
下面的图片可以点击查看更多细节,显示截至2024年3月,凯莱英(临时代码)的债务为1220万人民币,比一年前增加了。然而,其资产负债表显示其持有89.8亿元人民币的现金,所以它实际上有89.7亿元人民币的净现金。
How Healthy Is Asymchem Laboratories (Tianjin)'s Balance Sheet?
凯莱英(天津)的资产负债状况如何健康?
Zooming in on the latest balance sheet data, we can see that Asymchem Laboratories (Tianjin) had liabilities of CN¥1.77b due within 12 months and liabilities of CN¥466.2m due beyond that. On the other hand, it had cash of CN¥8.98b and CN¥1.85b worth of receivables due within a year. So it actually has CN¥8.59b more liquid assets than total liabilities.
放大最新的资产负债表数据,我们可以看到,凯莱英(天津)在12个月内有1770亿人民币的负债,而超过这一期限的负债为4662万元。另一方面,它有898亿人民币的现金和185亿人民币一年内到期的应收账款。所以,它实际上比总负债多了859亿人民币的流动性资产。
This surplus strongly suggests that Asymchem Laboratories (Tianjin) has a rock-solid balance sheet (and the debt is of no concern whatsoever). With this in mind one could posit that its balance sheet means the company is able to handle some adversity. Simply put, the fact that Asymchem Laboratories (Tianjin) has more cash than debt is arguably a good indication that it can manage its debt safely.
这种盈余强烈表明凯莱英(天津)有一个坚实的资产负债表(且债务完全无忧)。考虑到这一点,人们可以说,它的资产负债表意味着公司能够应对一些逆境。简单地说,凯莱英(天津)拥有的现金超过债务,可以说是一个很好的指标,表明它可以安全地管理债务。
In fact Asymchem Laboratories (Tianjin)'s saving grace is its low debt levels, because its EBIT has tanked 49% in the last twelve months. Falling earnings (if the trend continues) could eventually make even modest debt quite risky. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Asymchem Laboratories (Tianjin)'s ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
事实上,凯莱英(天津)的救世主是其低债务水平,因为其EBIt在过去12个月中下跌了49%。下降的收益(如果这一趋势持续下去)可能会使即使是适度的债务也变得相当危险。在分析债务水平时,资产负债表是明显的起点。但是未来的收益远比任何东西都决定凯莱英(天津)维持健康资产负债表的能力。因此,如果您关注未来,可以查看这份免费报告,显示分析师的利润预测。
Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. While Asymchem Laboratories (Tianjin) has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. In the last three years, Asymchem Laboratories (Tianjin)'s free cash flow amounted to 34% of its EBIT, less than we'd expect. That's not great, when it comes to paying down debt.
最后,虽然税务人员可能喜欢会计利润,但贷款人只接受冰冷的现金。虽然凯莱英(天津)在资产负债表上有净现金,但仍值得关注其将利息和税前利润(EBIT)转化为自由现金流的能力,以帮助我们理解它是如何快速建立(或侵蚀)现金余额的。在过去三年中,凯莱英(天津)的自由现金流占其EBIT的34%,低于我们的预期。这在偿还债务方面并不好。
Summing Up
总之
While we empathize with investors who find debt concerning, you should keep in mind that Asymchem Laboratories (Tianjin) has net cash of CN¥8.97b, as well as more liquid assets than liabilities. So we are not troubled with Asymchem Laboratories (Tianjin)'s debt use. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. We've identified 1 warning sign with Asymchem Laboratories (Tianjin) , and understanding them should be part of your investment process.
尽管我们对债务感到担忧,但您应该注意到凯莱英(临时代码)的净现金为89.7亿人民币,流动资产超过负债。所以我们对凯莱英(临时代码)的债务使用并不担心。在分析债务水平时,资产负债表是一个显而易见的起点。然而,并不是所有的投资风险都存在于资产负债表中 - 远非如此。我们已经发现了凯莱英(临时代码)的1个警示信号,了解它们应该成为您投资过程的一部分。
If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.
如果在所有这些之后,您更感兴趣的是具有坚实资产负债表的快速增长公司,那么不要拖延,查看我们的净现金增长股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。